Recall of Compounded GLP-1 Injections Upgraded to Class II
A voluntary recall of 22 vials of compounded tirzepatide injections by Apothecary Pharma has been classified as Class II by the U.S. Food and Drug Administration, meaning exposure to the product may cause temporary or medically reversible adverse health consequences, though the probability of serious harm is considered low. The recall, initially announced last month, was issued due to a "lack of assurance of sterility," according to the FDA. The classification was updated this month.
The recall affects doses of tirzepatide, a GLP-1 receptor agonist used for diabetes and weight loss, that were compounded by the pharmacy. Specific lot and code information is available on the FDA's recall announcement. The agency noted that the compounding pharmacy, Apothecary Pharma, had previously received a warning letter from the FDA in December for failing to properly label drugs at its outsourcing facility in North Carolina. Some labels omitted active ingredients, quantities, adverse event reporting information, and directions for use.
Earlier FDA Warning Cited Serious Deficiencies
The December warning letter followed inspections in September 2024 and three visits in January and May 2025, during which investigators observed "serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk," according to the FDA. The recall now adds to a growing list of safety concerns surrounding compounded versions of popular GLP-1 medications.
Context: Boom in Compounded GLP-1s Raises Safety Questions
Compounded GLP-1s are custom-made versions or copies of brand-name drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, formulated by compounding pharmacies when brand-name products are in shortage or when patients require alternative formulations. The practice has surged amid explosive demand for GLP-1 medications; as the Los Angeles Times reported in March, about 1 in 8 U.S. adults currently take such drugs. However, compounded products do not undergo the same rigorous FDA review as approved medications, and their sterility and quality can vary.
Houston Pharmacy Drew 14 FDA Inspection Observations
The recall of Apothecary Pharma's tirzepatide comes as separate FDA inspection records for a Houston-area pharmacy reveal troubling conditions. According to Medical Daily, the Houston pharmacy behind recalled compounded tirzepatide vials drew 14 FDA inspection observations, including exposed skin and the use of research-grade ingredients. Those findings, documented on FDA Form 483, highlight persistent concerns about sterile compounding practices at facilities producing injectable GLP-1s.
The FDA has stepped up oversight of compounded GLP-1s. In addition to warning letters, the agency has warned about contamination risks at overseas suppliers of key ingredients. On October 19, the Los Angeles Times reported that U.S. inspectors found black mold and "gross contamination" at two Chinese factories making components for compounded GLP-1 drugs popular in America. Those findings raise further questions about the supply chain for compounded versions.
Perspective: Safety Concerns Could Reshape the Compounded GLP-1 Market
The latest recall and inspection findings underscore the risks patients face when opting for compounded GLP-1s, which are often cheaper and more accessible than brand-name versions but lack the same regulatory assurances. While the FDA has permitted compounding during shortages, the agency has repeatedly warned that compounded drugs are not FDA-approved and may contain impurities or be improperly sterilized.
For patients, the recall serves as a reminder to check lot numbers and consult their healthcare providers if they have concerns. For the compounding industry, increased scrutiny may lead to stricter enforcement and potentially tighter rules on sterile compounding. The FDA's warning letters and Form 483 observations signal that the agency is monitoring practices closely, and future recalls or enforcement actions could follow.
As demand for GLP-1 medications continues to grow, the balance between access and safety remains a central tension. The recall of Apothecary Pharma's tirzepatide, while limited in scope, reflects broader challenges in ensuring the quality of compounded injectables. Patients and providers are advised to monitor FDA announcements for updates.
What Patients Should Know
Patients using compounded tirzepatide should check whether their medication matches the recalled lots and contact their pharmacy or healthcare provider with questions. The FDA recommends reporting adverse events or quality issues through its MedWatch program. While the risk of serious harm from this recall is low, the event highlights the importance of sourcing medications from reputable, licensed compounding pharmacies and staying informed about regulatory actions.
Comments